Predictors of very early stroke recurrence in the point trial population

HIGHLIGHTS

• who: Natalie Bourand from the Using the data of the POINT trial, we sought to identify baseline clinical factors associated with risk of early recurrence of a secondary event within , days following initial minor stroke or TIAThe POINT trial was a prospective clinical, randomized clinical trial in , subjects that compared treatment with aspirin and clopidogrel to aspirin alone in preventing secondary events over , days following a TIA or minor ischemic stroke. Subjects were randomized within , hours following the incident TIA or minor ischemic stroke. The design, methods, outcome definitions, and results of the POINT trial have been . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.